Sanofi and MD Anderson Cancer Center jointly develop innovative cancer therapies

"Our goal is to improve outcomes for a range of patients with difficult cancer, and the best way to achieve this is through a deep understanding of how new drugs work," said DrPeter Adamson, Head of Global Development for Oncology and Pediatric Innovation at Sanofi Oncology and Pediatricsthis will allow us to make decisions faster and help us more accurately identify potential new combinations and indicationsthis will save valuable time and help us expand the range of patients who may benefit from our treatment" MD Anderson Cancer Center manages one of the largest cancer clinical trial programs in the United States, with a comprehensive tissue collection, molecular and immunological analysis, and data analysis platformthis infrastructure enables comprehensive research of tumor samples taken before, during and after treatment to uncover valuable insights, simplify patient screening, and accelerate the identification of new combinations of therapies and indications"Clinical trials not only help us advance new life-saving treatments for patients in need, they also provide us with valuable information on which treatments may be more effective for which patients," said DrFunda Meric-Bernstam, Chair of Research Cancer Therapy at MD Anderson Cancer Center" the new alliance will also support the investigation of additional indications and combination drug use for already in-clinical research projectsScientists at the sanofi and MD Anderson Cancer Center,, will collaborate on experimental design, applying a core set of biomarkers and detection methodsthejoint project will also apply sanofi-developed new candidate drugs to existing tumor samples to obtain further data on their effectiveness at different stages of the diseasenew discoveries, as well as large-scale molecular and phenotype data sets, will be applied to the design of specific Sanofi molecules in the field of new transformational research and guide the choice of indicationsthe first projects are expected to be launched in the summer of 2020References: sanofi and MD Anderson announce strategic collaboration to accelerate ystyin research and developmentRetrieved July 14, 2020, from